Acceptability and safety and of treatment
nausea or vomiting, bronchitis, deaths, COPD, diabetes
ADVERSE EVENTS, COPD, BRONCHITIS, URINARY TRACT INFECTION, DIABETES
Of those who fulfilled the entry criteria only three patients (3%) who were eligible on screening (n = 96) declined to be enrolled after completing the consenting process. Of those who were consented and included all subjects completed the intravenous part of the study (100%). Two subjects stopped oral treatment in hospital for adverse events (see below). At follow-up, 25 of 29 (86%) self-reported taking vitamin C and 20 of 22 (91%) taking placebo to complete their course of treatment at home.Thirty-one adverse events in the 30 days from randomisation were reported. There were 8 serious adverse events, including 2 deaths, and two readmissions for CAP (Table The other 20 adverse events reported were: prescription of further antibiotic therapy from their general practitioner (vitamin C 7, placebo 5); worsening of existing health conditions (vitamin C 2, diabetes control and exacerbation of COPD); deconditioning after admission to hospital (vitamin C 1, placebo 1); new episode of bronchitis (placebo 1) and urinary tract infection (vitamin C 1); nausea or vomiting after enrolment but prior to administration of the intervention (vitamin C 1, placebo 1).